Kelun Biotech (6990.HK): Earnings Review: 1H sac-TMT sales beat; Lung06data as major focus with novel ADCs entering clinical stage-20260818
18 August 2026 | 12:34AM HKT Equity Research Kelun Biotech (6990.HK): Earnings Review: 1H sac-TMT sales beat; Lung06 data as major focus with novel ADCs entering clinical stage 1H product sales beat, expect steady R&D increase as pipeline expands: 1H product sales of Rmb657mn came stronger than expectations (+112% y/y, vs. GSe Rmb600mn, or VA consensus Rmb530mn) with encouraging sales ramp-up of sac-TMT in China driven by the NRDL inclusion (currently covering late-line TNBC and EGFRmut NSCLC). Though 1H li ...